SAB Biotherapeutics’ (SABS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $6.00 target price on the stock.

Separately, Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Buy” and an average target price of $11.40.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $1.20 on Tuesday. The firm has a 50 day moving average of $1.93 and a two-hundred day moving average of $2.82. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69. SAB Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $5.01.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Friday, March 28th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.07). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. The company had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.12 million. On average, equities analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Northern Trust Corp purchased a new stake in SAB Biotherapeutics during the fourth quarter worth approximately $43,000. Kovitz Investment Group Partners LLC purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $52,000. Diadema Partners LP purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth approximately $114,000. Geode Capital Management LLC boosted its holdings in shares of SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after buying an additional 12,692 shares in the last quarter. Finally, HB Wealth Management LLC grew its position in shares of SAB Biotherapeutics by 118.6% in the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after buying an additional 128,800 shares during the last quarter. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.